Document is current
Any future updates will be listed below
-
Authors
Cresswell, George D. https://orcid.org/0000-0003-3303-068X
Nichol, Daniel https://orcid.org/0000-0003-2662-1836
Spiteri, Inmaculada
Tari, Haider https://orcid.org/0000-0002-9407-489X
Zapata, Luis https://orcid.org/0000-0002-1386-2019
Heide, Timon https://orcid.org/0000-0002-1386-7469
Maley, Carlo C. https://orcid.org/0000-0002-0745-7076
Magnani, Luca https://orcid.org/0000-0002-7534-0785
Schiavon, Gaia
Ashworth, Alan
Barry, Peter
Sottoriva, Andrea https://orcid.org/0000-0001-6709-9533
-
Funding
Funding for this research was provided by:
Wellcome Trust (202778/B/16/Z)
Cancer Research UK (A22909)
- License Information
-
More Information
Article History
Received: 7 August 2019
Accepted: 18 February 2020
First Online: 27 March 2020
Competing interests
: G.S. is employee of AstraZeneca UK and also shareholder. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation; a consultant for SPARC, Bluestar, TopoRx, ProLynx; a member of the SAB of Genentech and GLAdiator; receives grant/research support from SPARC and AstraZeneca; A.A. holds patents on the use of PARP inhibitors held jointly with AstraZeneca which he has benefitted financially (and may do so in the future) through the ICR Rewards to Inventors Scheme.
